Central nervous system antiretroviral penetration and cognitive functioning in largely pretreated HIV-infected patients

Journal of NeuroVirology

Volumn 20, Issue 1, 2014, Pages 54-61

  Casado, José L ^a   Marín, Ana ^a   Moreno, Ana ^a   Iglesias, Verónica ^a   Perez Elías, María J ^a   Moreno, Santiago ^a   Corral, Iñigo ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

CNS; CPE; HIV; Neurocognitive; Penetration; Viral suppression

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; LOPINAVIR; NEVIRAPINE; TENOFOVIR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG PENETRATION; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; PRIORITY JOURNAL; SALVAGE THERAPY; SCORING SYSTEM;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COGNITION; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PREVALENCE;

EID: 84896717958     PISSN: 13550284     EISSN: 15382443     Source Type: Journal    
DOI: 10.1007/s13365-013-0228-0     Document Type: Article

References (29)

1. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M et al (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789-1799
2. Antinori A, Giancola ML, Grisetti S, Soldani F, Alba L, Liuzzi G et al (2002) Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients. AIDS 16:1867-1876
3. Bhaskaran K, Mussini C, Antinori A, Walker AS, Dorrucci M, Sabin C et al (2008) Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol 63:213-221
4. Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG et al (2010) Discordances between cerebrospinal fluid and plasma replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 50:773-8. doi: 10.1086/650538
5. Cysique L, Maruff P, Brew B (2004) Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol 10:350-357
6. Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP et al (2009) Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 73:342-348. doi: 10.1212/WNL.0b013e3181ab2b3b
7. d'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C et al (2004) Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 55:320-328
8. Eggers C, Hertogs K, Sturenburg HJ, van Lunzen J, Stellbrink HJ (2003) Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS 17:1897-1906
9. Ellis RJ, Evans SR, Clifford DB, Moo LR, McArthur JC, Collier AC et al (2005) Clinical validation of the NeuroScreen. J Neurovirol 11(6):503-511
10. Ellis RJ, Gamst AC, Capparelli E, Spector SA, Hsia K, Wolfson T et al (2000) Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology 54:927-936
11. Ellis RJ, Moore DJ, Childers ME, Letendre S, McCutchan JA, Wolfson T et al (2002) Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol 59:923-928
12. Giancola ML, Lorenzini P, Balestra P, Larussa D, Baldini F, Corpolongo A et al (2006) Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 41:332-337
13. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S et al (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17:3-16
14. Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H et al (2004) The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 10:317-331
15. Letendre S (2011) Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med 19:137-42
16. Letendre S, McClernon D, Ellis R, et al. (2009). Persistent HIV in the central nervous system during treatment is associated with worse ART penetration and cognitive impairment. [Abstract 484b.] 16th Conference on Retroviruses and Opportunistic Infections (CROI). February 8-11; Montreal, Canada.
17. Perez-Valero I, Arribas JR (2011) Protease inhibitor monotherapy. Curr Op Infect Dis 24:7-11. doi: 10.1097/QCO.0b013e3283422cdf
18. Price RW, Deeks SG (2004) Antiretroviral drug treatment interruption in human immunodeficiency virus infected adults: clinical and pathogenetic implications for the central nervous system. J Neurovirol 10(Suppl 1):44-51
19. Robertson KR, Smurzynski M, Parsons T, Wu K, Bosch R, Wu J et al (2007) The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 21:1915-1921
20. Sacktor N, McDermott M, Marder K, Schifitto G, Selnes OA, McArthur JC et al (2002) HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 8:136-142
21. Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V et al (2010) Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24:1243-1250. doi: 10.1097/QAD.0b013e3283354a7b
22. Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, Clifford DB et al (2011) Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 25:357-365. doi: 10.1097/QAD. 0b013e32834171f8
23. Tamarit MDP, Quereda C, Gonzalez-Rozas M, Corral I, Casado JL (2012) HIV-1 viral encephalitis after development of viral resistance to plasma suppressive antiretroviral therapy. AIDS Res Hum Retroviruses 28:83-86. doi: 10.1089/AID.2011.0020
24. Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori MF, Visco-Comandini U et al (2007) Persistence of neuropsychological deficits despite long-term HAART in patients with HIV-related neurocognitive impairment. Prevalence and risk factors. J Acquir Immune Defic Syndr 45:174-182
25. Tozzi V, Balestra P, Murri R, Galgani S, Bellagamba R, Narciso P et al (2004) Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART. Int J STD AIDS 15:254-259
26. Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML et al (2009) Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr 52:56-63
27. Varatharajan L, Thomas SA (2009) The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res 82:99-109. doi: 10.1016/j.antiviral.2008.12.013
28. Yilmaz A, Svennerholm B, Hagberg L, Gisslen M (2006) Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy. Antivir Ther 11:833-837
29. Zigmond AS, Snaith RP (1984) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361-370